- Report
- January 2026
Global
From €4472EUR$4,900USD£3,832GBP
- Report
- June 2024
- 200 Pages
Global
From €7256EUR$7,950USD£6,218GBP
- Report
- May 2024
- 134 Pages
Global
From €2737EUR$2,999USD£2,346GBP
€3650EUR$3,999USD£3,128GBP
- Report
- August 2023
- 367 Pages
Global
From €2282EUR$2,500USD£1,955GBP
The Arthralgia Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. It is composed of drugs used to treat arthralgia, which is a type of joint pain. These drugs are typically used to reduce inflammation and pain, and can be administered orally, topically, or through injection. Commonly used drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs).
The Arthralgia Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, Novartis, Sanofi, and AbbVie. Other companies include Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. Show Less Read more